Eyenovia Stock Soars 66.37% on Merger Talks, Regulatory Filing Plans

On May 20, 2025, Eyenovia's stock surged by 66.37% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Eyenovia has been actively engaged in merger negotiations with Betaliq, with both companies working towards a binding merger agreement. The exclusivity period for these negotiations has been extended until June 7, 2025, indicating a continued effort to finalize the deal.

In addition to the merger talks, Eyenovia is making progress with its Optejet user-filled device. The company plans to file for U.S. regulatory approval of the device in September 2025, which could be a pivotal moment for the company's growth and market presence.

Eyenovia also reported its financial results for the first quarter of 2025, providing insights into its operational performance and financial health. These updates, along with the ongoing merger discussions and regulatory filings, are likely contributing to the recent surge in the company's stock price.